ALPHAMAB-B (09966): The first patient in the Phase I clinical trial of JSKN027 has been given medication.

ALPHAMAB-B (09966) announced that the Phase I clinical study of JSKN027, a novel programed cell death ligand 1 (PD-L1)/vascular endothelial growth factor receptor 2 (VEGFR2) bispecific antibody-drug conjugate (ADC), for the treatment of advanced solid tumors, has successfully dosed its first patient. JSKN027 is the company's fifth ADC entering clinical development and the first PD-L1/VEGFR2 bispecific antibody ADC to enter clinical development globally. Based on its multiple mechanisms of action including cytotoxicity, anti-angiogenesis, and immune modulation, JSKN027 is expected to provide new treatment options for various solid tumors. The JSKN027-101 study is an open-label, multicenter, Phase I clinical trial conducted in patients with advanced malignant solid tumors, consisting of dose escalation and dose expansion stages. The study aims to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and preliminary anti-tumor activity of JSKN027 in patients with advanced malignancies, as well as to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).